An excellent example of the former approach is shown in a study by Fiandra et al. which compared the use of antibody fragments to the parent full antibody for imaging HER2 positive tumours.103 Iron oxide nanoparticles modified with a fluorescent dye were targeted towards HER2 cells using full trastuzumab, trastuzumab half antibody (consisting of a single heavy chain and a single light chain), or a trastuzumab derived ScFv. Here, ERBB2 is linked to neoplasm.